@article{dc6ebea9b147440f821bae73c88d27e0,
title = "Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial",
abstract = "Adjuvant high-dose interferon alfa-2b improves relapse-free survival (RFS) in patients with high-risk melanoma, although benefits in overall survival are uncertain. Because of the toxic effects of high-dose regimens, intermediate doses are being explored. We investigated whether adjuvant therapy with intermediate-dose interferon alfa-2b for 1 or 2 years would improve outcomes in patients with stage IIB-IIC or III resected cutaneous melanoma.",
keywords = "Adolescent, Adult, Aged, Antineoplastic Agents, Chemotherapy, Adjuvant, Disease-Free Survival, Dose-Response Relationship, Drug, Female, Humans, Interferon-alpha, Male, Melanoma, Middle Aged, Recombinant Proteins, Risk Factors, Time Factors",
author = "Johan Hansson and Steinar Aamdal and Lars Bastholt and Yvonne Brandberg and Micaela Hernberg and Nilsson, {Bo Ruby} and Ulrika Stierner and {von der Maase}, Hans and {Nordic Melanoma Cooperative Group}",
note = "Copyright {\textcopyright} 2011 Elsevier Ltd. All rights reserved.",
year = "2011",
month = feb,
doi = "10.1016/S1470-2045(10)70288-6",
language = "English",
volume = "12",
pages = "144--52",
journal = "Lancet Oncology",
issn = "1470-2045",
publisher = "The/Lancet Publishing Group",
number = "2",
}